EPHEDRINE THRESHOLD ELIMINATION PROPOSAL BY DEA WILL CREATE "DE FACTO BAN"
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE THRESHOLD ELIMINATION PROPOSAL BY DEA WILL CREATE "DE FACTO BAN" of single-entity ephedrine sold in OTC bronchodilators, BDI Pharmaceuticals maintained in April 29 comments to the Drug Enforcement Administration. The company objected to a proposal published by DEA in the March 17 Federal Register to eliminate the regulatory threshold that currently exempts the sale of certain amounts of ephedrine from reporting and recordkeeping requirements under the Controlled Substances Act.